ClinicalTrials.gg
CompletedNCT05451914Updated Nov 20, 2026Results posted

Effects of My Diabetes Care on Patient Outcomes

An interventional study of My Diabetes Care in Diabetes Mellitus, Type 2, sponsored by Vanderbilt University Medical Center. Completed at 2 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-20.

Sponsored by Vanderbilt University Medical Center · Not applicable, Interventional, and Health services research

How we know

Updated Nov 20, 2026Results postedStudy documents posted+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
458
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 21 studies in Diabetes Mellitus, Type 2 by Vanderbilt University Medical Center — 4 open to participants now, 5 under way, none of them phase 3. Diabetes Mellitus, Type 2 · Vanderbilt University Medical Center.

Enrollment
6th of 18
458 · median 135
Started
2023
the only one that year
No phase
13 of 21
2 open now
Registered
15th of 21
by date

Among the 21 studies in Diabetes Mellitus, Type 2 by Vanderbilt University Medical Center, this one is the 6th largest by enrollment of the 18 interventional ones that give a count, is the only one that started in 2023, is one of 13 with no phase, and was the 15th registered.

Diabetes Mellitus, Type 2

10,403 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

4 of the 21 studies in Diabetes Mellitus, Type 2 by Vanderbilt University Medical Center are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 882 Diabetes Mellitus, Type 2 studies recruiting now, 372 (42%) set no upper age limit and 384 (44%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies in Diabetes Mellitus, Type 2 by Vanderbilt University Medical Center, or all of them as a file.
02

Study summary

The purpose of this study is to conduct a two-arm, parallel-design, pragmatic randomized controlled trial of a patient portal intervention for diabetes, My Diabetes Care (MDC), to evaluate its effect on clinical outcomes.

Read the detailed description

484 adult patients with type 2 diabetes mellitus will be randomized to one of two arms. 242 will be assigned to the intervention (My Diabetes Care) embedded within an existing patient web portal, My Health at Vanderbilt at Vanderbilt University Medical Center or Patient Gateway at Brigham and Women's Hospital. 242 will be assigned to a usual care comparison arm with access currently available version of My Health at Vanderbilt or Patient Gateway without the My Diabetes Care (MDC) application. Potentially eligible patients will be invited to be screened for enrollment in the study. Interested patients will be able to complete an electronic consent form and enroll online via Research Electronic Data Capture (REDCap). Outcomes data will be collected from patients at four time points: baseline (T0), three-month follow-up (T1), three-month follow-up (T2), six-month follow-up (T3), and twelve-month follow-up (T4). At each time point, study participants will complete questionnaires electronically via email using REDCap, participants' hemoglobin A1C level will be assess via home A1C test kits, and participants' diabetes health data will be abstracted from their electronic health record. Participants will be randomized to the intervention or control arm after their baseline data is collected.

03

Conditions studied

  • Diabetes Mellitus, Type 2

Keywords

  • Diabetes
  • Patient Web Portals
  • Health Information Technology
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Type 2 Diabetes Mellitus
  • Age 18-75 years old
  • Currently taking at least one medication for diabetes
  • Be a patient at Vanderbilt University Medical Center (VUMC) or Brigham and Women's Hospital (BWH)
  • Able to speak and read in English or Spanish
  • Have reliable access to a smartphone, tablet, or computer with internet access
  • Active patient web portal account (My Health at Vanderbilt at VUMC or Patient Gateway at BWH)

Exclusion criteria

Exclusion Criteria:

  • Receiving dialysis,
  • Pregnant or planning to become pregnant within the next year,
  • Living in a long-term care facility.
05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
458 participants (actual)

Study arms

  • Experimental
    My Diabetes Care

    Patients have access to an existing patient web portal (i.e., Epic's MyChart) embedded with My Diabetes Care.

    Other: My Diabetes Care

  • No intervention
    Usual Care

    Patients will have access to an existing patient web portal (i.e., Epic's MyChart) NOT embedded with My Diabetes Care (i.e., usual care)

Interventions

  • OtherMy Diabetes Care

    My Diabetes Care (MDC) is a multi-faceted patient portal intervention for mobile devices that is designed to help patients better understand their diabetes health data as well as promote and support self-management. MDC uses infographics to facilitate patients' understanding of their diabetes health data (e.g., HbA1c, LDL) and provides literacy level-appropriate and tailored diabetes self-care information.

    Also known as: Patient-facing Diabetes Dashboard

06

What researchers measure

Primary outcomes

  1. Change in Blood Glucose Control at 6 Months

    Hemoglobin A1c will assessed using mail-in home HbA1c test kits and participants' most recent hemoglobin A1C will be abstracted from participants' electronic medical record.

    Time frame: Baseline (T0) to Six-month Follow-Up (T2)

Secondary outcomes

  1. Change in Body Mass Index (BMI)

    Participants' most recent body mass index (BMI) measurement will be abstracted from participants' electronic medical record.

    Time frame: Baseline (T0), Three-month Follow-up (T1), Six-month Follow-Up (T2), Twelve-month Follow-up (T3)

  2. Change in Low Density Lipoprotein (LDL)

    Participants' most recent low density lipoprotein (LDL) measurement will be abstracted from participants' electronic medical record.

    Time frame: Baseline (T0), Three-month Follow-up (T1), Six-month Follow-Up (T2), Twelve-month Follow-up (T3)

  3. Urine Albumin-to-Creatinine Ratio

    Participants' most albumin-to-creatinine ratio will be abstracted from participants' electronic medical record.

    Time frame: Baseline (T0), Three-month Follow-up (T1), Six-month Follow-Up (T2), Twelve-month Follow-up (T3)

  4. Change in Systolic Blood Pressure

    Participants' most recent systolic blood pressure measurement will be abstracted from participants' electronic medical record.

    Time frame: Baseline (T0), Three-month Follow-up (T1), Six-month Follow-Up (T2), Twelve-month Follow-up (T3)

  5. Change in Diabetes Self-Care (General Diet Adherence)

    The Summary of Diabetes Self-Care Activity (SDSCA) is a 10-item multidimensional instrument to assess levels of diabetes self-care across five domains: general diet (2 items), specific diet (2 items), exercise (2 items), foot care (2 items), and blood-glucose testing (2 items). The general diet subscale is used to assess general diet adherence. The instrument is based on the self-reported days completing recommended activities during the past 7 days. An example item includes "How many of the last SEVEN DAYS have you followed a healthful eating plan?" The general diet subscale score is the mean number of days for the 2 items in the subscale. The score range is from 0 days (worst) to 7 days (best).

    Time frame: Baseline (T0), Three-month Follow-up (T1), Six-month Follow-Up (T2), Twelve-month Follow-up (T3)

  6. Change in Diabetes Self-Care (Exercise Adherence)

    The Summary of Diabetes Self-Care Activity (SDSCA) is a 10-item multidimensional instrument to assess levels of diabetes self-care across five domains: general diet (2 items), specific diet (2 items), exercise (2 items), foot care (2 items), and blood-glucose testing (2 items). The exercise subscale is used to assess exercise adherence. The instrument is based on the self-reported days completing recommended activities during the past 7 days. An example item includes "On how many of the last SEVEN DAYS did you participate in at least 30 minutes of physical activity?" The exercise subscale score is the mean number of days for the 2 items in the subscale. The score range is from 0 days (worst) to 7 days (best).

    Time frame: Baseline (T0), Three-month Follow-up (T1), Six-month Follow-Up (T2), Twelve-month Follow-up (T3)

  7. Change in Diabetes Self-Care (Diabetes Medication Adherence)

    The Adherence to Refills and Medications Scale-Diabetes (ARMS-D) is a reliable and valid measure of diabetes medication adherence. The 11-item ARMS-D has good internal consistency reliability (α=0.86). Responses range from 1="none of the time" to 4="all of the time," and are summed to produce an overall adherence score ranging from 11-44, with higher scores representing more problems with medication adherence.

    Time frame: Baseline (T0), Three-month Follow-up (T1), Six-month Follow-Up (T2), Twelve-month Follow-up (T3)

  8. Change in Diabetes Self-Care (Self-Monitoring of Blood Glucose Adherence)

    The Summary of Diabetes Self-Care Activity (SDSCA) is a 10-item multidimensional instrument to assess levels of diabetes self-care across five domains: general diet (2 items), specific diet (2 items), exercise (2 items), foot care (2 items), and blood-glucose testing (2 items). The blood-glucose testing subscale is used to assess self-monitoring of blood glucose adherence. The instrument is based on the self-reported days completing recommended activities during the past 7 days. An example item includes "On how many of the last SEVEN DAYS did you test your blood sugar?" The blood-glucose testing subscale is the mean number of days for the 2 items in the subscale. The score range is from 0 days (worst) to 7 days (best).

    Time frame: Baseline (T0), Three-month Follow-up (T1), Six-month Follow-Up (T2), Twelve-month Follow-up (T3)

  9. Usability of MyChart (for Control Group)

    The usability of the patient portal (Epic's MyChart) will be assessed using the System Usability Scale (SUS). The SUS is a valid measure of usability and assesses users' perceptions of ease of use, likability of the interface, and overall satisfaction using a 5- point Likert scale (strongly disagree to strongly agree). The ten items are scored on a five-point Likert scale. The item scores are summed and then converted to a score ranging from 0 (worst) to 100 (best). Based on prior research, a score above 68 would be above average and a score of 85 or above suggests excellent usability.

    Time frame: Twelve-month Follow-up (T3)

  10. Satisfaction/Usability of My Diabetes Care (for Intervention Group)

    The usability of the My Diabetes Care will be assessed using the System Usability Scale (SUS). The SUS is a valid measure of usability and assesses users' perceptions of ease of use, likability of the interface, and overall satisfaction using a 5- point Likert scale (strongly disagree to strongly agree). The ten items are scored on a five-point Likert scale. The item scores are summed and then converted to a score ranging from 0 (worst) to 100 (best). Based on prior research, a score above 68 would be above average and a score of 85 or above suggests excellent usability.

    Time frame: Twelve-month Follow-up (T3)

  11. Change in Diastolic Blood Pressure

    Participants' most recent diastolic blood pressure measurement will be abstracted from participants' electronic medical record.

    Time frame: Baseline (T0), Three-month Follow-up (T1), Six-month Follow-Up (T2), Twelve-month Follow-up (T3)

  12. Change in Blood Glucose Control at 12 Months

    Hemoglobin A1c will assessed using mail-in home HbA1c test kits and participants' most recent hemoglobin A1C will be abstracted from participants' electronic medical record.

    Time frame: Baseline (T0) to Twelve-month Follow-Up (T3)

07

Results

Posted Nov 20, 2026

Participant flow

Participant flow — Overall Study
MilestoneMy Diabetes CareUsual Care
Started221220
Completed216214
Not completed56
Withdrew: Withdrawal by subject55
Withdrew: Death01

Outcome measures

PrimaryChange in Blood Glucose Control at 6 Months

Hemoglobin A1c will assessed using mail-in home HbA1c test kits and participants' most recent hemoglobin A1C will be abstracted from participants' electronic medical record.

Time frame:
Baseline (T0) to Six-month Follow-Up (T2)
Reported as:
Mean · percentage of glycated hemoglobin
Change in Blood Glucose Control at 6 Months
percentage of glycated hemoglobinMy Diabetes CareUsual Care
Change in Blood Glucose Control at 6 Months-0.6 ± 1.4-0.5 ± 1.4
Statistical analysis
  • My Diabetes Care vs Usual Care · t-test, 2 sided · p = 0.38 · Mean difference (net): -0.1
SecondaryChange in Body Mass Index (BMI)

Participants' most recent body mass index (BMI) measurement will be abstracted from participants' electronic medical record.

Time frame:
Baseline (T0), Three-month Follow-up (T1), Six-month Follow-Up (T2), Twelve-month Follow-up (T3)
Reported as:
Mean · kg/m²
Change in Body Mass Index (BMI)
kg/m²My Diabetes CareUsual Care
Baseline (T0) to 3-months (T1)-0.5 ± 1.6-0.4 ± 1.6
Baseline (T0) to 6-months (T2)-0.8 ± 2.2-0.7 ± 2.0
Baseline (T0) to 12-months (T3)-1.3 ± 3.0-1.1 ± 3.3
Statistical analysis
  • My Diabetes Care vs Usual Care · t-test, 2 sided · p = 0.81 · Mean difference (net): -0.1
  • My Diabetes Care vs Usual Care · t-test, 2 sided · p = 0.61 · Mean difference (net): -0.1
  • My Diabetes Care vs Usual Care · t-test, 2 sided · p = 0.55 · Mean difference (net): -0.2
SecondaryChange in Low Density Lipoprotein (LDL)

Participants' most recent low density lipoprotein (LDL) measurement will be abstracted from participants' electronic medical record.

Time frame:
Baseline (T0), Three-month Follow-up (T1), Six-month Follow-Up (T2), Twelve-month Follow-up (T3)
Reported as:
Mean · mg/dL
Change in Low Density Lipoprotein (LDL)
mg/dLMy Diabetes CareUsual Care
Baseline (T0) to 3-months (T1)11.0 ± 52.62.2 ± 33.1
Baseline (T0) to 6-months (T2)5.5 ± 32.7-18.7 ± 33.0
Baseline (T0) to 12-months (T3)2.5 ± 21.9-11.8 ± 26.1
Statistical analysis
  • My Diabetes Care vs Usual Care · t-test, 2 sided · p = 0.80 · Mean difference (net): 8.8
  • My Diabetes Care vs Usual Care · t-test, 2 sided · p = 0.13 · Mean difference (net): 24.2
  • My Diabetes Care vs Usual Care · t-test, 2 sided · p = 0.10 · Mean difference (net): 14.3
SecondaryUrine Albumin-to-Creatinine Ratio

Participants' most albumin-to-creatinine ratio will be abstracted from participants' electronic medical record.

Time frame:
Baseline (T0), Three-month Follow-up (T1), Six-month Follow-Up (T2), Twelve-month Follow-up (T3)
Reported as:
Mean · mcg/mg
Urine Albumin-to-Creatinine Ratio
mcg/mgMy Diabetes CareUsual Care
Baseline (T0) to 3-months (T1)-14.2 ± 18.7—
Baseline (T0) to 6-months (T2)41.4 ± 123.1-225.9 ± 390.6
Baseline (T0) to 12-months (T3)-25.6 ± 84.283.5 ± 305.9
Statistical analysis
  • My Diabetes Care vs Usual Care · t-test, 2 sided · p = 0.36 · Mean difference (net): 267.3
  • My Diabetes Care vs Usual Care · t-test, 2 sided · p = 0.24 · Mean difference (net): -109.1
SecondaryChange in Systolic Blood Pressure

Participants' most recent systolic blood pressure measurement will be abstracted from participants' electronic medical record.

Time frame:
Baseline (T0), Three-month Follow-up (T1), Six-month Follow-Up (T2), Twelve-month Follow-up (T3)
Reported as:
Mean · mmHg
Change in Systolic Blood Pressure
mmHgMy Diabetes CareUsual Care
Baseline (T0) to 3-months (T1)-4.4 ± 19.8-3.1 ± 15.3
Baseline (T0) to 6-months (T2)-2.2 ± 18.8-1.1 ± 16.1
Baseline (T0) to 12-months (T3)0.9 ± 18.4-4.0 ± 17.2
Statistical analysis
  • My Diabetes Care vs Usual Care · t-test, 2 sided · p = 0.60 · Mean difference (net): -1.3
  • My Diabetes Care vs Usual Care · t-test, 2 sided · p = 0.66 · Mean difference (net): -1.1
  • My Diabetes Care vs Usual Care · t-test, 2 sided · p = 0.04 · Mean difference (net): 4.9
SecondaryChange in Diabetes Self-Care (General Diet Adherence)

The Summary of Diabetes Self-Care Activity (SDSCA) is a 10-item multidimensional instrument to assess levels of diabetes self-care across five domains: general diet (2 items), specific diet (2 items), exercise (2 items), foot care (2 items), and blood-glucose testing (2 items). The general diet subscale is used to assess general diet adherence. The instrument is based on the self-reported days completing recommended activities during the past 7 days. An example item includes "How many of the last SEVEN DAYS have you followed a healthful eating plan?" The general diet subscale score is the mean number of days for the 2 items in the subscale. The score range is from 0 days (worst) to 7 days (best).

Time frame:
Baseline (T0), Three-month Follow-up (T1), Six-month Follow-Up (T2), Twelve-month Follow-up (T3)
Reported as:
Mean · score on a scale
Change in Diabetes Self-Care (General Diet Adherence)
score on a scaleMy Diabetes CareUsual Care
Baseline (T0) to 3-months (T1)0.2 ± 1.30.2 ± 1.3
Baseline (T0) to 6-months (T2)0.3 ± 1.30.2 ± 1.3
Baseline (T0) to 12-months (T3)0.4 ± 1.20.2 ± 1.3
Statistical analysis
  • My Diabetes Care vs Usual Care · t-test, 2 sided · p = 1.00 · Mean difference (net): 0
  • My Diabetes Care vs Usual Care · t-test, 2 sided · p = 0.58 · Mean difference (net): 0.1
  • My Diabetes Care vs Usual Care · t-test, 2 sided · p = 0.13 · Mean difference (net): 0.2
SecondaryChange in Diabetes Self-Care (Exercise Adherence)

The Summary of Diabetes Self-Care Activity (SDSCA) is a 10-item multidimensional instrument to assess levels of diabetes self-care across five domains: general diet (2 items), specific diet (2 items), exercise (2 items), foot care (2 items), and blood-glucose testing (2 items). The exercise subscale is used to assess exercise adherence. The instrument is based on the self-reported days completing recommended activities during the past 7 days. An example item includes "On how many of the last SEVEN DAYS did you participate in at least 30 minutes of physical activity?" The exercise subscale score is the mean number of days for the 2 items in the subscale. The score range is from 0 days (worst) to 7 days (best).

Time frame:
Baseline (T0), Three-month Follow-up (T1), Six-month Follow-Up (T2), Twelve-month Follow-up (T3)
Reported as:
Mean · score on a scale
Change in Diabetes Self-Care (Exercise Adherence)
score on a scaleMy Diabetes CareUsual Care
Baseline (T0) to 3-months (T1)0.2 ± 1.80.4 ± 1.7
Baseline (T0) to 6-months (T2)0.3 ± 1.90.4 ± 2.0
Baseline (T0) to 12-months (T3)0.4 ± 1.80.3 ± 1.9
Statistical analysis
  • My Diabetes Care vs Usual Care · t-test, 2 sided · p = 0.28 · Mean difference (net): -0.2
  • My Diabetes Care vs Usual Care · t-test, 2 sided · p = 0.73 · Mean difference (net): -0.1
  • My Diabetes Care vs Usual Care · t-test, 2 sided · p = 0.71 · Mean difference (net): 0.1
SecondaryChange in Diabetes Self-Care (Diabetes Medication Adherence)

The Adherence to Refills and Medications Scale-Diabetes (ARMS-D) is a reliable and valid measure of diabetes medication adherence. The 11-item ARMS-D has good internal consistency reliability (α=0.86). Responses range from 1="none of the time" to 4="all of the time," and are summed to produce an overall adherence score ranging from 11-44, with higher scores representing more problems with medication adherence.

Time frame:
Baseline (T0), Three-month Follow-up (T1), Six-month Follow-Up (T2), Twelve-month Follow-up (T3)
Reported as:
Mean · score on a scale
Change in Diabetes Self-Care (Diabetes Medication Adherence)
score on a scaleMy Diabetes CareUsual Care
Baseline (T0) to 3-months (T1)-0.1 ± 3.1-0.3 ± 3.0
Baseline (T0) to 6-months (T2)-0.1 ± 3.6-0.2 ± 3.4
Baseline (T0) to 12-months (T3)0 ± 3.3-0.2 ± 3.4
Statistical analysis
  • My Diabetes Care vs Usual Care · t-test, 2 sided · p = 0.53 · Mean difference (net): 0.2
  • My Diabetes Care vs Usual Care · t-test, 2 sided · p = 0.78 · Mean difference (net): 0.1
  • My Diabetes Care vs Usual Care · t-test, 2 sided · p = 0.49 · Mean difference (net): 0.2
SecondaryChange in Diabetes Self-Care (Self-Monitoring of Blood Glucose Adherence)

The Summary of Diabetes Self-Care Activity (SDSCA) is a 10-item multidimensional instrument to assess levels of diabetes self-care across five domains: general diet (2 items), specific diet (2 items), exercise (2 items), foot care (2 items), and blood-glucose testing (2 items). The blood-glucose testing subscale is used to assess self-monitoring of blood glucose adherence. The instrument is based on the self-reported days completing recommended activities during the past 7 days. An example item includes "On how many of the last SEVEN DAYS did you test your blood sugar?" The blood-glucose testing subscale is the mean number of days for the 2 items in the subscale. The score range is from 0 days (worst) to 7 days (best).

Time frame:
Baseline (T0), Three-month Follow-up (T1), Six-month Follow-Up (T2), Twelve-month Follow-up (T3)
Reported as:
Mean · score on a scale
Change in Diabetes Self-Care (Self-Monitoring of Blood Glucose Adherence)
score on a scaleMy Diabetes CareUsual Care
Baseline (T0) to 3-months (T1)0.1 ± 2.40.1 ± 2.3
Baseline (T0) to 6-months (T2)0.3 ± 2.20 ± 2.4
Baseline (T0) to 12-months (T3)0.2 ± 2.60.2 ± 2.6
Statistical analysis
  • My Diabetes Care vs Usual Care · t-test, 2 sided · p = 0.75 · Mean difference (net): 0
  • My Diabetes Care vs Usual Care · t-test, 2 sided · p = 0.30 · Mean difference (net): 0.3
  • My Diabetes Care vs Usual Care · t-test, 2 sided · p = 0.97 · Mean difference (net): 0
SecondaryUsability of MyChart (for Control Group)

The usability of the patient portal (Epic's MyChart) will be assessed using the System Usability Scale (SUS). The SUS is a valid measure of usability and assesses users' perceptions of ease of use, likability of the interface, and overall satisfaction using a 5- point Likert scale (strongly disagree to strongly agree). The ten items are scored on a five-point Likert scale. The item scores are summed and then converted to a score ranging from 0 (worst) to 100 (best). Based on prior research, a score above 68 would be above average and a score of 85 or above suggests excellent usability.

Time frame:
Twelve-month Follow-up (T3)
Reported as:
Mean · score on a scale
Usability of MyChart (for Control Group)
score on a scaleMy Diabetes CareUsual Care
Usability of MyChart (for Control Group)—79.3 ± 15.5
SecondarySatisfaction/Usability of My Diabetes Care (for Intervention Group)

The usability of the My Diabetes Care will be assessed using the System Usability Scale (SUS). The SUS is a valid measure of usability and assesses users' perceptions of ease of use, likability of the interface, and overall satisfaction using a 5- point Likert scale (strongly disagree to strongly agree). The ten items are scored on a five-point Likert scale. The item scores are summed and then converted to a score ranging from 0 (worst) to 100 (best). Based on prior research, a score above 68 would be above average and a score of 85 or above suggests excellent usability.

Time frame:
Twelve-month Follow-up (T3)
Reported as:
Mean · score on a scale
Satisfaction/Usability of My Diabetes Care (for Intervention Group)
score on a scaleMy Diabetes CareUsual Care
Satisfaction/Usability of My Diabetes Care (for Intervention Group)75.0 ± 15.6—
SecondaryChange in Diastolic Blood Pressure

Participants' most recent diastolic blood pressure measurement will be abstracted from participants' electronic medical record.

Time frame:
Baseline (T0), Three-month Follow-up (T1), Six-month Follow-Up (T2), Twelve-month Follow-up (T3)
Reported as:
Mean · mmHg
Change in Diastolic Blood Pressure
mmHgMy Diabetes CareUsual Care
Baseline (T0) to 3-months (T1)-1.3 ± 10.7-0.3 ± 10.6
Baseline (T0) to 6-months (T2)-2.2 ± 10.2-1.0 ± 12.0
Baseline (T0) to 12-months (T3)-1.8 ± 10.4-2.1 ± 10.3
Statistical analysis
  • My Diabetes Care vs Usual Care · t-test, 2 sided · p = 0.49 · Mean difference (net): -1.0
  • My Diabetes Care vs Usual Care · t-test, 2 sided · p = 0.40 · Mean difference (net): -1.2
  • My Diabetes Care vs Usual Care · t-test, 2 sided · p = 0.85 · Mean difference (net): 0.3
SecondaryChange in Blood Glucose Control at 12 Months

Hemoglobin A1c will assessed using mail-in home HbA1c test kits and participants' most recent hemoglobin A1C will be abstracted from participants' electronic medical record.

Time frame:
Baseline (T0) to Twelve-month Follow-Up (T3)
Reported as:
Mean · percentage of glycated hemoglobin
Change in Blood Glucose Control at 12 Months
percentage of glycated hemoglobinMy Diabetes CareUsual Care
Change in Blood Glucose Control at 12 Months-0.5 ± 1.8-0.6 ± 1.6
Statistical analysis
  • My Diabetes Care vs Usual Care · t-test, 2 sided · p = 0.52 · Mean difference (net): 0.1

Adverse events

Collected over 12 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
My Diabetes Care0/221 (0%)5/221 (2.3%)0/221 (0%)
Usual Care1/220 (0.5%)6/220 (2.7%)0/220 (0%)
Most frequent serious events
Most frequent serious events
EventMy Diabetes CareUsual Care
HospitalizationInfections and infestations1/2213/220
HospitalizationGastrointestinal disorders2/2210/220
HospitalizationGeneral disorders1/2211/220
HospitalizationsMusculoskeletal and connective tissue disorders0/2211/220
DeathNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/2211/220
HospitalizationCardiac disorders1/2210/220

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)My Diabetes CareUsual CareTotal
<=18 years000
Between 18 and 65 years166163329
>=65 years5557112
Age, Continuous
Age, Continuous(years)My Diabetes CareUsual CareTotal
Mean56.3 ± 11.256.1 ± 11.156.2 ± 11.2
Sex/Gender, Customized
Sex/Gender, Customized(Participants)My Diabetes CareUsual CareTotal
Female110107217
Male109113222
Other101
Missing101
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)My Diabetes CareUsual CareTotal
Hispanic or Latino91928
Not Hispanic or Latino211200411
Unknown or Not Reported112
Race (NIH/OMB)
Race (NIH/OMB)(Participants)My Diabetes CareUsual CareTotal
American Indian or Alaska Native101
Asian13720
Native Hawaiian or Other Pacific Islander000
Black or African American384280
White153158311
More than one race9716
Unknown or Not Reported7613
Region of Enrollment
Region of Enrollment(participants)My Diabetes CareUsual CareTotal
United States221220441
Language(s) Spoken
Language(s) Spoken(Participants)My Diabetes CareUsual CareTotal
English — Yes216218434
English — No527
Spanish — Yes12921
Spanish — No209211420
Other — Yes6713
Other — No215213428
08

Study locations

2 sites
  • Brigham and Women's Hospital
    Boston, Massachusetts 02115, United States
  • Vanderbilt University Medical Center
    Nashville, Tennessee 37232, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — After study results are posted on clinical trials and published in a peer-reviewed journal, de-identified individual participant data that underlie the results reported will be available upon requests made to the principal investigator and ending after 36 months after publication.

Supporting information: Study protocol, Statistical analysis plan

Time frame: Deidentified individual participant data that underlie the results reported will be available after publication in a peer-reviewed journal and posted on clinical trials and ending after 36 months of publication.

Access criteria: Researchers should provide a methodologically sound proposal to achieve their proposed aims. Proposals may be submitted to the principal investigator up to 36 months following publication. To gain access, data requestors will need to sign a data access agreement.

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2023 to primary completion in Jul 2025, 24 months.

Results were first posted in Nov 2026, 1 year 4 months after primary completion.

Of 2,078 non-industry interventional studies with no phase under Diabetes Mellitus, Type 2, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 40. This study's 24 months is above that.

Counting every sponsor, half of 2,255 studies reached it within 21 months; a quarter within 10 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 1, 2022
First posted
Jul 11, 2022
StartActual
Jul 6, 2023
Primary completionActual
Jul 14, 2025
CompletionActual
Jul 14, 2025
Results first posted
Nov 20, 2026
Last update
Nov 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Nov 20, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • EditedChange in Blood Glucose Control at 6 MonthsTime frame: Baseline (T0), Three-month Follow-up (T1), Six-month Follow-Up (T2), Twelve-month Follow-up (T3) → Baseline (T0) to Six-month Follow-Up (T2)
Nov 20, 2026
Documents
Secondary outcomes
1 edited, 2 time frame changed, 2 added, 1 description edited
What changed in the outcomes
  • EditedChange in Systolic Blood Pressure ControlTime frame: Baseline (T0), Three-month Follow-up (T1), Six-month Follow-Up (T2), Twelve-month Follow-up (T3)
  • AddedChange in Diastolic Blood PressureTime frame: Baseline (T0), Three-month Follow-up (T1), Six-month Follow-Up (T2), Twelve-month Follow-up (T3)
  • AddedChange in Blood Glucose Control at 12 MonthsTime frame: Baseline (T0) to Twelve-month Follow-Up (T3)
  • Time frameUsability of MyChart (for Control Group)Baseline (T0), Three-month Follow-up (T1), Six-month Follow-Up (T2), Twelve-month Follow-up (T3) → Twelve-month Follow-up (T3)
  • Time frameSatisfaction/Usability of My Diabetes Care (for Intervention Group)Baseline (T0), Three-month Follow-up (T1), Six-month Follow-Up (T2), Twelve-month Follow-up (T3) → Twelve-month Follow-up (T3)
  • DescriptionChange in Diabetes Self-Care (Diabetes Medication Adherence): how it is measured was reworded
Nov 20, 2026
Show all 1 update
  1. Nov 20, 2026
    Results posted
    Primary outcomes 1 edited
    What changed in the outcomes
    • EditedChange in Blood Glucose Control at 6 MonthsTime frame: Baseline (T0), Three-month Follow-up (T1), Six-month Follow-Up (T2), Twelve-month Follow-up (T3) → Baseline (T0) to Six-month Follow-Up (T2)
    Secondary outcomes 1 edited, 2 time frame changed, 2 added, 1 description edited
    What changed in the outcomes
    • EditedChange in Systolic Blood Pressure ControlTime frame: Baseline (T0), Three-month Follow-up (T1), Six-month Follow-Up (T2), Twelve-month Follow-up (T3)
    • AddedChange in Diastolic Blood PressureTime frame: Baseline (T0), Three-month Follow-up (T1), Six-month Follow-Up (T2), Twelve-month Follow-up (T3)
    • AddedChange in Blood Glucose Control at 12 MonthsTime frame: Baseline (T0) to Twelve-month Follow-Up (T3)
    • Time frameUsability of MyChart (for Control Group)Baseline (T0), Three-month Follow-up (T1), Six-month Follow-Up (T2), Twelve-month Follow-up (T3) → Twelve-month Follow-up (T3)
    • Time frameSatisfaction/Usability of My Diabetes Care (for Intervention Group)Baseline (T0), Three-month Follow-up (T1), Six-month Follow-Up (T2), Twelve-month Follow-up (T3) → Twelve-month Follow-up (T3)
    • DescriptionChange in Diabetes Self-Care (Diabetes Medication Adherence): how it is measured was reworded
    + 2 other changes: verification date and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT05451914
Responsible party
William Martinez, MD, MS (Assistant Professor of Medicine, Vanderbilt University Medical Center) — Principal investigator
First posted
Jul 11, 2022
Start date
Jul 6, 2023
Primary completion
Jul 14, 2025
Completion
Jul 14, 2025
Results posted
Nov 20, 2026
Last update
Nov 20, 2026

Study contacts

William Martinez, MD, MS
principal investigator · Vanderbilt University Medical Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion